Alvim, CeciliaMansinho, AndréPaiva, Rita S.Brás, RaquelSemedo, Patrícia M.Lobo-Martins, Soraiada Ponte, Carolina B.Macedo, DanielaRibeiro, Maria Leonordos Reis, José PFernandes, IsabelCosta, Luis2021-12-092021-12-092020Future Sci OA. 2019 Dec 12;6(2):FSO4362056-5623http://hdl.handle.net/10451/50320© Cecilia Melo Alvim. This work is licensed under the Creative Commons Attribution4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evaluation of patients with mCRPC treated with AA. Results: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10-0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14-0.41; p < 0.001). Conclusion: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA.engAbiraterone acetateMetastatic castration-resistant prostate cancerProstate-specific antigen responsejournal article10.2144/fsoa-2019-0079